$OYST News
Last published 2y ago
- 2y agoOYSTApproval of Tyrvaya, Nda #213978 (Labeling)FDA Approved DrugsApproval Date: 02/02/2024; Drug Name: Tyrvaya, Nda #213978; Active Ingredients: VARENICLINE TARTRATE; Company: Oyster Point Pharma; Submission Status: Approval; Submission Classification: Labeling; Application Number: 213978
- 3y agoOYSTNasal Spray Study in Sjogren's Dry Eye Disease - NCT05700422ClinicalTrials.govMean change in cornea and conjunctival staining, Mean change in eye dryness score as measured by the Visual Analogue Scale (VAS), Mean change in best corrected visual acuity, (and 3 more...)
- 3y agoOYSTOyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development
- 4y agoOYSTVTRSOyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswireTYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately
- 4y agoOYSTOYST Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Oyster Point Pharma, Inc.GlobeNewswireMONSEY, New York, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of Oyster Point Pharma, Inc. (NASDAQ:OYST) ("Oyster") acted in the best interests of
- 4y agoOYSTVTRSOyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by ViatrisGlobeNewswireTender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point
- 4y agoOYSTOyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022GlobeNewswirePRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class
- 4y agoOYSTOyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development
- 4y agoOYSTPharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease - NCT05576415ClinicalTrials.govCmax of varenicline after the first dosing at Visit 1 [Day 1] and after the last dosing at Visit 3 [Day 28], respectively., Tmax of varenicline after the first dosing at Visit 1 [Day 1] and after the last dosing at Visit 3 [Day 28], respectively., AUCtau(Area under the concentration-time curve during a dosing interval) of varenicline after the first dosing at Visit 1 [Day 1] and after the last dos ...
- 4y agoOYSTAn Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity - NCT05566717ClinicalTrials.govPrimary Endpoint
- 4y agoOYSTOyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in
- 4y agoOYSTOyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIIIGlobeNewswirePRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in
- 4y agoOYSTOyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-i
- 4y agoOYSTOyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer SymposiumGlobeNewswirePRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat op
- 4y agoOYSTOyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit ManagerGlobeNewswirePRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-
- 4y agoOYSTOyster Point Pharma To Attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022GlobeNewswirePRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-
- 4y agoOYSTOyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswireTYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2'22 Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 5,700 Unique Eye Care Professionals; Launch to D
- 4y agoOYSTOyster Point Pharma, Inc. (OYST) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsOYST earnings call for the period ending June 30, 2022.
- 4y agoOYSTOyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022GlobeNewswireConference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and
- 4y agoOYSTOyster Point Pharma Announces Expanded Patient Access to TYRVAYA®GlobeNewswireTYRVAYA Now Covered by Commercial Prescription Drug Plans Managed by the Nation's Top Three Pharmacy Benefit Manager (PBM) Group Purchasing Organizations (GPOs) Expanding Patient Access Programs to Include More Eligible Patients with Dry Eye Disease L
- 4y agoOYSTOyster Point Pharma Announces Operating Expense Streamlining PlanGlobeNewswirePlan to Continue to Drive TYRVAYA® Launch with Approximately 150-200 Field-Based Sales Resources Plan Expected to Deliver Expense Savings of Approximately $6-8 Million in the Second Half of 2022 and $40-48 Million in 2023 Company to Refocu
- 4y agoOYSTOyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®GlobeNewswirePRINCETON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat op
- 4y agoOYSTOyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswireTYRVAYA® Nasal Spray Net Product Revenue of $2.7 Million in Q1'22 Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care Professionals Expansion of Commercial Coverage for TYRVAY
- 4y agoOYSTOyster Point Pharma, Inc. (OYST) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsOYST earnings call for the period ending March 31, 2022.
- 4y agoOYSTOyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022GlobeNewswirePRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophth
- 4y agoOYSTOyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022GlobeNewswirePRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat o
- 4y agoOYSTOyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022GlobeNewswirePRINCETON, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat o
- 4y agoOYSTOyster Point Pharma Announces Retirement of William J. Link From Board of DirectorsGlobeNewswirePRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat op
- 4y agoOYSTOyster Point Pharma to Participate in the Cowen 42nd Annual Health Care ConferenceGlobeNewswirePRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat op
- 4y agoOYSTOyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business HighlightsGlobeNewswireFDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021 TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in Q4'21, plus $5.4 Million Recognized from Ji Xing P
- 4y agoOYSTOyster Point Pharma, Inc. (OYST) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsOYST earnings call for the period ending December 31, 2021.
- 4y agoOYSTOyster Point Pharma Announces TYRVAYA™ Nasal Spray Now Covered by Express ScriptsGlobeNewswireOne of the largest pharmacy benefit management (PBM) companies in the United States has added TYRVAYA (varenicline solution) Nasal Spray to National Preferred, Basic and High-Performance Formularies, effective February 19, 2022. FDA Approved TYRVAY
- 4y agoOYSTOyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022GlobeNewswirePRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat oph
- 4y agoOYSTOyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat op
- 4y agoOYSTOyster Point Pharma to Present at Upcoming Investor Conferences in January 2022GlobeNewswirePRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat
- 4y agoOYSTNBIOyster Point Pharma Announces Addition To Nasdaq Biotechnology IndexGlobeNewswirePRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat oph
- 4y agoOYSTOyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare ConferenceGlobeNewswirePRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat
- 4y agoOYSTOyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye DiseaseGlobeNewswirePRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat oph
- 4y agoOYSTOyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal SprayGlobeNewswirePRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-cl
- 5y agoOYSTOyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021GlobeNewswirePRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat oph
- 5y agoOYSTOyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewswireFDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021 Field Force Onboarding Completed During Q3'21, U.S. Launch of TYRVAYA Nasal Spray Initiated on Nov. 1st. TY
- 5y agoOYSTOyster Point Pharma, Inc. (OYST) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsOYST earnings call for the period ending September 30, 2021.
- 5y agoOYSTOyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of Dry Eye DiseaseGlobeNewswireOyster Point has launched a patient support program called TEAMTyrvaya™ TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease PRINCETON, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oyster
- 5y agoOYSTOyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021GlobeNewswirePRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat oph
- 5y agoOYSTOyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021GlobeNewswirePRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocu
- 5y agoBVNCIDMFSTXOYST+1Thinking about buying stock in Oyster Point Pharma, Tegna, Compania de Minas Buenaventura, F-Star Therapeutics, or Cinedigm?PR NewswireNEW YORK, Oct. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OYST, TGNA, BVN, FSTX, and CIDM. T
- 5y agoADMPINMIOOYST+1Thinking about buying stock in Ion Geophysical, Valneva SE, Adamis Pharmaceuticals, Oyster Point Pharma, or InMed Pharmaceuticals?PR NewswireNEW YORK, Oct. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, VALN, ADMP, OYST, and INM. To
- 5y agoOYSTOyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye DiseasePR NewswirePRINCETON, N.J., Oct. 18, 2021 /PRNewswire/ -- Oyster Point Pharma, Inc. (NASDAQ:OYST), today announced that the U.S. Food and Drug Administration (FDA) has approved TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg for the treatment of th
- 5y agoOYSTApproval of Tyrvaya, Nda #213978 (Type 3 - New Dosage Form)FDA Approved DrugsApproval Date: 10/15/2021; Drug Name: Tyrvaya, Nda #213978; Active Ingredients: VARENICLINE; Company: Oyster Point Pharma Inc; Submission Status: Approval; Submission Classification: Type 3 - New Dosage Form; Application Number: 213978
- 5y agoOYSTOyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (NASDAQ:OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat oph